Actively Recruiting
Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion
Led by Samsung Medical Center · Updated on 2026-02-09
3500
Participants Needed
2
Research Sites
467 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
I
Inje University Ilsan Paik Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a prospective, open label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective percutaneous coronary intervention with drug eluting stents for complex coronary lesions.
CONDITIONS
Official Title
Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 19 years old
- Able to verbally confirm understanding of risks, benefits, and treatment alternatives and provide written informed consent
- Undergoing elective PCI for complex coronary lesions including true bifurcation lesions with side branch 5.5 mm, chronic total occlusion of at least 3 months, unprotected left main disease, long coronary lesions with expected stent length 38 mm, multi-vessel PCI with 2 or more vessels treated in one session, multiple stents needed (3 or more), in-stent restenosis lesion, severely calcified lesion, or ostial lesions of major coronary arteries
You will not qualify if you...
- Hemodynamic instability or cardiogenic shock
- History of serious bleeding events such as intracerebral hemorrhage, gastrointestinal bleeding, hematuria, or hemoptysis
- Previous intracerebral hemorrhage, transient ischemic attack, or stroke
- Known allergy or contraindication to aspirin, clopidogrel, or prasugrel
- Females of childbearing potential without a recent negative pregnancy test or planning pregnancy after enrollment
- Non-cardiac conditions with life expectancy less than 1 year or likely to cause non-compliance
- Patients with biomarker positive acute coronary syndrome
- Chronic use of prasugrel or ticagrelor for 1 week or more
- Age 75 or older or body weight less than 60 kg
- Current use of warfarin or novel oral anticoagulants such as dabigatran, rivaroxaban, edoxaban, or apixaban
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
2
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
J
Joo-Yong Hahn, MD, PhD
CONTACT
K
Ki hong Choi, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here